December 1, 2016 09:15 AM EST
News Briefing

Mag­ic mush­rooms treat de­pres­sion, anx­i­ety felt by can­cer pa­tients; Mer­ck wins a speedy re­view sched­ule for lat­est Keytru­da ini­tia­tive

Shehla Shakoor

Managing Director

Yes­ter­day’s sto­ry about the po­ten­tial use of an il­lic­it drug for a neu­ropsy­chi­atric con­di­tion fo­cused on MD­MA (ec­sta­sy) for post-trau­mat­ic stress dis­or­der. To­day we …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times